JP2020063241A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020063241A5 JP2020063241A5 JP2019185670A JP2019185670A JP2020063241A5 JP 2020063241 A5 JP2020063241 A5 JP 2020063241A5 JP 2019185670 A JP2019185670 A JP 2019185670A JP 2019185670 A JP2019185670 A JP 2019185670A JP 2020063241 A5 JP2020063241 A5 JP 2020063241A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- linker
- tate
- targeting moiety
- conjugate according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000011096 Somatostatin receptor family Human genes 0.000 claims 8
- 108050001286 Somatostatin receptor family Proteins 0.000 claims 8
- ASCUXPQGEXGEMJ-GPLGTHOPSA-N [(2R,3S,4S,5R,6S)-3,4,5-triacetyloxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(4-methylanilino)oxan-2-yl]methoxy]oxan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@H]1OC[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](NC=2C=CC(C)=CC=2)O1 ASCUXPQGEXGEMJ-GPLGTHOPSA-N 0.000 claims 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 6
- DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims 4
- 125000001711 D-phenylalanine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229960002700 Octreotide Drugs 0.000 claims 2
- 108010016076 Octreotide Proteins 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000005418 aryl aryl group Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- KEKAEHDXIJNAIJ-TWVRELQASA-N (2S,3R)-2-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-hydroxybutanoic ac Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)C1=CC=CC=C1 KEKAEHDXIJNAIJ-TWVRELQASA-N 0.000 claims 1
- SWXOGPJRIDTIRL-HFQRKYADSA-N (4R,7S,10S,13S,16S,19R)-10-(4-aminobutyl)-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-HFQRKYADSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000002019 disulfides Chemical class 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 229960002730 vapreotide Drugs 0.000 claims 1
Claims (20)
- コンジュゲート又はその薬学的に許容される塩であって、リンカーによりソマトスタチン受容体(SSTR)標的部分と結合された活性薬を含み、前記コンジュゲートの分子量が5,000Da未満であり、前記活性薬がメルタンシン(DM1)であり、前記SSTR標的部分が、
シクロ(AA−Tyr−DTrp−Lys−Thr−Phe)、
Tyr 3 −オクトレオテート(TATE)、
オクトレオチド、
バプレオチド、
D−Phe残基のフェニル環が前記リンカーと交換されたオクトレオチド誘導体、
D−Phe残基のフェニル環が前記リンカーと交換されたTATE誘導体
のうちから選択されるペプチドである、コンジュゲート。 - 前記リンカーは切断不能なリンカーである、請求項1に記載のコンジュゲート。
- 前記リンカーは切断可能なリンカーである、請求項1に記載のコンジュゲート。
- 前記リンカーは、エステル結合、ジスルフィド、アミド、アシルヒドラゾン、エーテル、カルバメート、カーボネート、又は尿素を含む、請求項1に記載のコンジュゲート。
- 前記SSTR標的部分がシクロ(AA−Tyr−DTrp−Lys−Thr−Phe)である、請求項1に記載のコンジュゲート。
-
の構造を有する、請求項5に記載のコンジュゲート。 - 下記の化合物のいずれかから選択される、請求項5に記載のコンジュゲート。
- 前記SSTR標的部分がTyr 3 −オクトレオテート(TATE)である、請求項1に記載のコンジュゲート。
- 前記リンカーが共有結合によりTATEのC末端に結合しており、
前記コンジュゲートが
の構造を有し、式中、
Rは、H、アルキル、アリール、及びアミド基のうちから選択され、
Ar 1 及びAr 2 は独立して、ヘテロシクリル、アリール、及びヘテロアリール基のうちから選択される、請求項8に記載のコンジュゲート。 - 前記リンカーとTATEとの間の結合がアミド結合である、請求項8に記載のコンジュゲート。
- 下記の化合物のいずれかから選択される、請求項8に記載のコンジュゲート。
- 前記SSTR標的部分がオクトレオチド、バプレオチド、又はTATEであり、前記リンカーが前記SSTR標的部分のN末端に結合している、請求項1に記載のコンジュゲート。
-
の構造を有し、式中、
R 1 及びR 2 は独立して、H、OH、アルキル、アリール、カルボニル、エステル、アミド、エーテル、アルコール、又はアミンから選択され、
Ar 1 は、1つ以上の基で任意に置換される、ヘテロシクリル、アリール、及びヘテロアリール基から選択される、請求項12に記載のコンジュゲート。 - 下記の化合物のいずれかから選択される、請求項12に記載のコンジュゲート。
- 前記SSTR標的部分が、D−Phe残基のフェニル環が前記リンカーと交換されたオクトレオチド誘導体又はD−Phe残基のフェニル環が前記リンカーと交換されたTATE誘導体である、請求項1に記載のコンジュゲート。
-
の構造を有し、式中、
Rは、H、OH、アルキル、アリール、カルボニル、エステル、アミド、エーテル、アルコール、又はアミンから選択される、請求項15に記載のコンジュゲート。 - 下記の化合物のいずれかから選択される、請求項15に記載のコンジュゲート。
- 請求項1〜17のいずれか一項に記載のコンジュゲート及び少なくとも1つの薬学的に許容される賦形剤を含む医薬製剤。
- 癌の治療薬の製造における、請求項1〜17のいずれか一項に記載のコンジュゲートの使用。
- 腫瘍成長、腫瘍サイズ、又は腫瘍体積を抑制するための医薬の製造における、請求項1〜17のいずれか一項に記載のコンジュゲートの使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021131359A JP2021175757A (ja) | 2014-06-30 | 2021-08-11 | 標的化コンジュゲートならびにその粒子及び製剤 |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462019001P | 2014-06-30 | 2014-06-30 | |
US62/019,001 | 2014-06-30 | ||
US201462077487P | 2014-11-10 | 2014-11-10 | |
US62/077,487 | 2014-11-10 | ||
US201562150413P | 2015-04-21 | 2015-04-21 | |
US62/150,413 | 2015-04-21 | ||
JP2017500064A JP6602834B2 (ja) | 2014-06-30 | 2015-06-30 | 標的化コンジュゲートならびにその粒子及び製剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017500064A Division JP6602834B2 (ja) | 2014-06-30 | 2015-06-30 | 標的化コンジュゲートならびにその粒子及び製剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021131359A Division JP2021175757A (ja) | 2014-06-30 | 2021-08-11 | 標的化コンジュゲートならびにその粒子及び製剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020063241A JP2020063241A (ja) | 2020-04-23 |
JP2020063241A5 true JP2020063241A5 (ja) | 2020-06-11 |
JP6932389B2 JP6932389B2 (ja) | 2021-09-08 |
Family
ID=55020088
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017500064A Expired - Fee Related JP6602834B2 (ja) | 2014-06-30 | 2015-06-30 | 標的化コンジュゲートならびにその粒子及び製剤 |
JP2019185670A Active JP6932389B2 (ja) | 2014-06-30 | 2019-10-09 | 標的化コンジュゲートならびにその粒子及び製剤 |
JP2021131359A Pending JP2021175757A (ja) | 2014-06-30 | 2021-08-11 | 標的化コンジュゲートならびにその粒子及び製剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017500064A Expired - Fee Related JP6602834B2 (ja) | 2014-06-30 | 2015-06-30 | 標的化コンジュゲートならびにその粒子及び製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021131359A Pending JP2021175757A (ja) | 2014-06-30 | 2021-08-11 | 標的化コンジュゲートならびにその粒子及び製剤 |
Country Status (15)
Country | Link |
---|---|
US (4) | US9750818B2 (ja) |
EP (1) | EP3160518A4 (ja) |
JP (3) | JP6602834B2 (ja) |
KR (2) | KR20190143491A (ja) |
CN (2) | CN110478495A (ja) |
AU (2) | AU2015284236B2 (ja) |
BR (1) | BR212016030926U2 (ja) |
CA (1) | CA2953371C (ja) |
IL (1) | IL249647B (ja) |
MX (1) | MX2017000080A (ja) |
PH (1) | PH12017500023A1 (ja) |
RU (1) | RU2695220C2 (ja) |
SG (1) | SG11201610880RA (ja) |
WO (1) | WO2016004048A2 (ja) |
ZA (1) | ZA201608432B (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9533054B2 (en) * | 2013-03-11 | 2017-01-03 | Shanghai Jiao Tong University | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof |
WO2016004048A2 (en) | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
BR112017028552A2 (pt) * | 2015-06-30 | 2018-09-04 | Tarveda Therapeutics Inc | partículas e conjugados direcionados e formulações dos mesmos |
WO2017011685A1 (en) * | 2015-07-15 | 2017-01-19 | Celator Pharmaceuticals, Inc. | Improved nanoparticle delivery systems |
WO2017075495A1 (en) * | 2015-10-28 | 2017-05-04 | Tarveda Therapeutics, Inc. | Sstr-targeted conjugates and particles and formulations thereof |
US10039801B2 (en) | 2016-02-16 | 2018-08-07 | Strongbridge Ireland Limited | Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use |
US20190085034A1 (en) * | 2016-03-16 | 2019-03-21 | Tarveda Therapeutics, Inc. | Antibody mimic conjugates and particles |
WO2017180834A1 (en) * | 2016-04-13 | 2017-10-19 | Tarveda Therapeutics, Inc. | Neurotensin receptor binding conjugates and formulations thereof |
WO2017210246A2 (en) * | 2016-05-31 | 2017-12-07 | Tarveda Therapeutics, Inc. | Penicillamine conjugates and particles and formulations thereof |
US20210317156A1 (en) * | 2016-08-31 | 2021-10-14 | Mireca Medicines Gmbh | New polymer linked multimers of guanosine-3', 5'-cyclic monophosphates |
SG11201903431SA (en) * | 2016-10-28 | 2019-05-30 | Tarveda Therapeutics Inc | Sstr-targeted conjugates and particles and formulations thereof |
WO2018222987A1 (en) * | 2017-06-01 | 2018-12-06 | Tarveda Therapeutics, Inc. | Targeted constructs |
MX2020000376A (es) * | 2017-07-11 | 2020-07-14 | Sustained Nano Systems Llc | Formulaciones farmaceuticas hipercomprimidas. |
CN107422021B (zh) * | 2017-07-14 | 2019-11-19 | 北京朗阅科技有限公司 | 琼脂糖胶囊及其制备方法与应用 |
EP3672618A4 (en) * | 2017-08-25 | 2021-07-07 | Nal Pharmaceutical Group Limited | COMPOSITIONS AND METHODS OF ADMINISTRATION OF PHARMACOLOGICAL AGENTS |
AU2018354364A1 (en) * | 2017-10-27 | 2020-05-07 | Tva (Abc), Llc | SSTR-targeted conjugates and formulations thereof |
AU2018386218A1 (en) * | 2017-12-14 | 2020-07-02 | Tva (Abc), Llc | HSP90-targeting conjugates and formulations thereof |
JP2021525766A (ja) * | 2018-06-01 | 2021-09-27 | ターベダ セラピューティクス インコーポレイテッドTarveda Therapeutics,Inc. | 併用療法 |
CN109124096B (zh) * | 2018-08-23 | 2021-08-06 | 广州百隆威尔精密五金制品有限公司 | 一种升降橱柜 |
WO2020125546A1 (zh) * | 2018-12-17 | 2020-06-25 | 荣昌生物制药(烟台)有限公司 | 一种用于抗体药物偶联物的连接子及其应用 |
EP3941508A1 (en) * | 2019-03-18 | 2022-01-26 | The Trustees of Columbia University in the City of New York | Non-hydrolyzable, non-cleavable, stable linkers for precision therapeutics and uses thereof |
CN109848440A (zh) * | 2019-04-10 | 2019-06-07 | 燕山大学 | 一种钯纳米立方体的制备方法 |
AU2020307561A1 (en) * | 2019-06-25 | 2022-01-20 | Tva (Abc), Llc | SSTR-targeted conjugates and formulations thereof |
CN112250647A (zh) * | 2020-06-30 | 2021-01-22 | 浙江大学 | 紫杉烷类药物前体、制备方法和应用 |
AU2021409394A1 (en) | 2020-12-21 | 2023-07-27 | Cornell University | Peptide-linked drug delivery system |
WO2022174171A1 (en) * | 2021-02-15 | 2022-08-18 | Anp Technologies, Inc. | Pharmaceutical composition containing taxane nanoaggregates and use thereof |
WO2022197988A1 (en) * | 2021-03-18 | 2022-09-22 | National Taiwan University | Lipid-based nanoparticle delivery system for hydrophilic charged compound |
EP4312941A1 (en) * | 2021-04-01 | 2024-02-07 | R.P. Scherer Technologies, LLC | Phospholipids as anion chelating agents in pharmaceutical formulations |
IT202100014330A1 (it) * | 2021-06-01 | 2022-12-01 | The Ubeauty Com Llc | Prodotto per la cura della pelle e procedimento per la sua realizzazione. |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5702717A (en) * | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
US5843903A (en) * | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
AT405906B (de) * | 1997-03-14 | 1999-12-27 | Irene Dr Virgolini | Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie |
US6358491B1 (en) * | 1999-08-27 | 2002-03-19 | Berlex Laboratories, Inc. | Somatostatin analogs |
AU1360901A (en) * | 1999-11-01 | 2001-05-14 | University Technology Corporation | Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing |
AU4267700A (en) * | 2000-01-13 | 2001-07-19 | Academia Sinica | Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells |
DE10006572A1 (de) * | 2000-02-14 | 2001-08-23 | Deutsches Krebsforsch | Oligonucleotid-Konjugate |
FR2824563B1 (fr) * | 2001-05-10 | 2004-12-03 | Bio Merieux | Particules composites, conjugues derives, procede de preparation et applications |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US8877901B2 (en) * | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
EP1531846A4 (en) | 2002-02-27 | 2006-04-19 | Us Gov Health & Human Serv | CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES |
US7771727B2 (en) | 2002-03-01 | 2010-08-10 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
PT1534340E (pt) * | 2002-09-06 | 2012-03-13 | Cerulean Pharma Inc | Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente |
TWI260228B (en) * | 2002-12-31 | 2006-08-21 | Ind Tech Res Inst | Delivery carrier of presenting cell of somatostatin receptor |
AU2004220530A1 (en) | 2003-03-10 | 2004-09-23 | Mpa Technologies, Inc. | Targeted agents for both photodiagnosis and photodynamic therapy |
JP4578470B2 (ja) * | 2003-04-22 | 2010-11-10 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | ソマトスタチンベクター |
US8088387B2 (en) * | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
CN1956722A (zh) * | 2003-05-20 | 2007-05-02 | 伊缪诺金公司 | 含有新的美登素类的改进的细胞毒剂 |
JP4318985B2 (ja) * | 2003-08-21 | 2009-08-26 | 日本メジフィジックス株式会社 | ソマトスタチンアナログ誘導体およびその利用 |
ES2503719T3 (es) * | 2005-02-11 | 2014-10-07 | Immunogen, Inc. | Procedimiento para preparar conjugados de anticuerpos y de maitansinoides |
IL305084A (en) | 2005-08-24 | 2023-10-01 | Immunogen Inc | A process for preparing purified drug compounds |
NZ566982A (en) | 2005-09-26 | 2011-06-30 | Medarex Inc | Duocarmycin drug conjugates |
EP1864682A1 (en) | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Leptomycin derivatives |
US10925977B2 (en) * | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
JP5631591B2 (ja) * | 2006-10-06 | 2014-11-26 | アムジエン・インコーポレーテツド | 安定な抗体製剤 |
CA3146422A1 (en) | 2008-03-18 | 2009-09-24 | Genentech, Inc. | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
BRPI0911442A2 (pt) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
BRPI0912230A2 (pt) | 2008-05-06 | 2017-08-22 | Glaxo Group Ltd | Método para encapsular agentes biologicamente ativos em um carreador particulado, carreador particulado, e, composição farmacêutica |
KR101324804B1 (ko) * | 2008-05-13 | 2013-11-01 | 아이알엠 엘엘씨 | 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물 |
US8680263B2 (en) * | 2008-09-19 | 2014-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
FR2945211A1 (fr) | 2009-05-06 | 2010-11-12 | Sanofi Aventis | Combinaison antitumorale comprenant la cabazitaxel et la capecitabine |
PL2449379T3 (pl) * | 2009-07-02 | 2017-12-29 | Sloan-Kettering Institute For Cancer Research | Fluorescencyjne nanocząstki na bazie krzemionki |
JP5892540B2 (ja) * | 2009-12-25 | 2016-03-23 | 国立研究開発法人理化学研究所 | 生体内にて標的組織に指向する放射標識化合物およびその利用 |
RU2012151296A (ru) * | 2010-04-30 | 2014-06-10 | Санва Кагаку Кенкюсо Ко., Лтд | Пептид для улучшения биостабильности биоактивного вещества и биоактивное вещество, имеющее повышенную биостабильность |
TW201302793A (zh) * | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
CA2810838C (en) * | 2010-09-08 | 2021-07-06 | The Board Of Regents Of The University Of Texas System | Somatostatin receptor-based cancer therapy |
WO2012118909A1 (en) * | 2011-03-01 | 2012-09-07 | Ge Healthcare Limited | Radiolabelled octreotate analogues as pet tracers |
WO2012138911A2 (en) * | 2011-04-05 | 2012-10-11 | The Administrators Of The Tulane Educational Fund | Conjugates of anti-hiv drugs and somatostatin analogs |
US9156854B2 (en) | 2011-04-18 | 2015-10-13 | Immunogen, Inc. | Maytansinoid derivatives with sulfoxide linker |
CA2836338C (en) * | 2011-05-16 | 2022-05-03 | Koninklijke Philips N.V. | Tetrazine derivatives used in bio-orthogonal drug activation |
JP6209159B2 (ja) | 2011-06-21 | 2017-10-04 | イミュノジェン・インコーポレーテッド | ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体 |
EP3406347A3 (en) * | 2012-02-27 | 2019-02-13 | Amunix Operating Inc. | Xten conjugate compositions and methods of making same |
MX363147B (es) * | 2012-09-17 | 2019-03-11 | Pfizer Inc Star | Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos para realizarlas y usarlas. |
WO2014134483A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
ES2741308T3 (es) | 2013-10-15 | 2020-02-10 | Scripps Research Inst | Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos |
WO2016004048A2 (en) | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
-
2015
- 2015-06-30 WO PCT/US2015/038569 patent/WO2016004048A2/en active Application Filing
- 2015-06-30 CN CN201910762952.XA patent/CN110478495A/zh active Pending
- 2015-06-30 RU RU2016151859A patent/RU2695220C2/ru active
- 2015-06-30 BR BR212016030926U patent/BR212016030926U2/pt active IP Right Grant
- 2015-06-30 AU AU2015284236A patent/AU2015284236B2/en not_active Ceased
- 2015-06-30 CA CA2953371A patent/CA2953371C/en active Active
- 2015-06-30 SG SG11201610880RA patent/SG11201610880RA/en unknown
- 2015-06-30 CN CN201580044836.4A patent/CN106573077B/zh active Active
- 2015-06-30 MX MX2017000080A patent/MX2017000080A/es unknown
- 2015-06-30 JP JP2017500064A patent/JP6602834B2/ja not_active Expired - Fee Related
- 2015-06-30 EP EP15815040.9A patent/EP3160518A4/en not_active Withdrawn
- 2015-06-30 KR KR1020197037860A patent/KR20190143491A/ko active Application Filing
- 2015-06-30 KR KR1020177002414A patent/KR102062025B1/ko active IP Right Grant
-
2016
- 2016-12-07 ZA ZA2016/08432A patent/ZA201608432B/en unknown
- 2016-12-16 US US15/382,487 patent/US9750818B2/en active Active
- 2016-12-19 IL IL249647A patent/IL249647B/en active IP Right Grant
-
2017
- 2017-01-03 PH PH12017500023A patent/PH12017500023A1/en unknown
- 2017-07-18 US US15/652,947 patent/US10624967B2/en not_active Expired - Fee Related
- 2017-07-18 US US15/652,957 patent/US10322191B2/en not_active Expired - Fee Related
-
2018
- 2018-06-07 AU AU2018204037A patent/AU2018204037B2/en not_active Ceased
-
2019
- 2019-10-09 JP JP2019185670A patent/JP6932389B2/ja active Active
-
2020
- 2020-02-18 US US16/793,094 patent/US11458206B2/en active Active
-
2021
- 2021-08-11 JP JP2021131359A patent/JP2021175757A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020063241A5 (ja) | ||
JP6092867B2 (ja) | 担体連結しているトレプロスチニルプロドラッグ | |
CN105814028B (zh) | 作为免疫调节剂的1,2,4‑*二唑衍生物 | |
US9096642B2 (en) | Therapeutic compounds for immunomodulation | |
JP7483776B2 (ja) | 放出制御pth化合物の漸増用量設定 | |
JP2020514300A5 (ja) | ||
US20060051315A1 (en) | Polymers for delivering peptides and small molecules in vivo | |
JP2010521485A5 (ja) | ||
RU2548905C2 (ru) | Терапевтические пептиды | |
US11077082B2 (en) | Composition and method for dual targeting in treatment of neuroendocrine tumors | |
JP2011184442A (ja) | Il−21の誘導体 | |
EP2485712A1 (en) | Subcutaneous paliperidone composition | |
US20170014524A1 (en) | Auristatin-antibody conjugates and uses thereof | |
CN110022896A (zh) | 新化合物及其治疗用途 | |
JP2018521977A5 (ja) | ||
KR101828613B1 (ko) | 올리고머-칼슘 모방체 컨쥬게이트 및 관련 화합물 | |
US8518891B2 (en) | Chemotherapeutic conjugates and methods of use | |
AU2018370019A1 (en) | Stable compositions of pegylated carfilzomib compounds | |
JP2007537244A (ja) | 20位にてインテグリンアンタゴニストと接合したカンプトテシン誘導体 | |
EP1372733B1 (en) | Pharmaceutical compositions of active polypeptides for enhanced pharmacological activity through oral and parenteral administration | |
US20070225311A1 (en) | 7-T-Butoxyiminomethylcamptothecin Conjugated in Position 20 With Integrin Antagonists | |
KR20170091610A (ko) | 신규 peg 유도체 | |
US11351137B2 (en) | Composition and method for dual targeting in treatment of neuroendocrine tumors | |
CA3220332A1 (en) | Composition and method for dual targeting in treatment of neuroendocrine tumors | |
US20220362278A1 (en) | Renal targeting-type drug delivery carrier having excellent biodegrability |